Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-20

Reporting Person: Krasner Alan Seth (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-20	Common Stock	P	2000	$17.00	Acquired	2000	Direct